ResMed Inc. (NYSE:RMD) Posts Quarterly Earnings Results, Meets Expectations

ResMed Inc. (NYSE:RMD) issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.66, Bloomberg Earnings reports. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company had revenue of $523.66 million for the quarter, compared to analyst estimates of $506.08 million. During the same quarter last year, the company posted $0.62 EPS. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year.

ResMed (NYSE:RMD) traded up $0.34 during trading hours on Friday, hitting $83.06. The company’s stock had a trading volume of 374,800 shares, compared to its average volume of 774,937. The stock has a market capitalization of $11,786.55, a P/E ratio of 28.94, a P/E/G ratio of 1.85 and a beta of 0.79. ResMed has a 12-month low of $57.45 and a 12-month high of $87.81. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be given a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 annualized dividend and a dividend yield of 1.69%. ResMed’s dividend payout ratio is currently 56.68%.

Several research firms recently weighed in on RMD. J P Morgan Chase & Co raised their price objective on ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Zacks Investment Research raised ResMed from a “sell” rating to a “hold” rating in a report on Monday, October 30th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Friday, September 8th. Northland Securities reaffirmed a “sell” rating and set a $55.00 target price on shares of ResMed in a report on Friday, October 27th. Finally, Barclays PLC lifted their price objective on ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a research report on Friday, October 27th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $67.57.

In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $77.56, for a total transaction of $96,950.00. Following the completion of the sale, the chief financial officer now directly owns 65,941 shares in the company, valued at $5,114,383.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Peter C. Farrell sold 20,000 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $83.53, for a total transaction of $1,670,600.00. Following the sale, the director now owns 314,800 shares of the company’s stock, valued at $26,295,244. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,842 shares of company stock worth $6,548,619. Company insiders own 1.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ResMed Inc. (NYSE:RMD) Posts Quarterly Earnings Results, Meets Expectations” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with's FREE daily email newsletter.

Leave a Reply